Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20588469 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2PSMB5PSMB8MAPTALOX15 | |
| SCHEMBL20587880 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2PSMB5MAPTALOX15THRB | |
| SCHEMBL9276591 | 0.83 | SMN1; SMN2 (0.75) | SMN1; SMN2MAPTALOX15THRBPOLB | |
| SCHEMBL20588781 | 0.82 | SMN1; SMN2 (0.73) | SMN1; SMN2PSMB5MAPTALOX15THRB | |
| SCHEMBL20588475 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTALOX15THRBPOLB | |
| SCHEMBL7568303 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2PSMB5PSMB8MAPTALOX15 | |
| SCHEMBL15211749 | 0.77 | POLB (0.54) | SMN1; SMN2MAPTTHRBPOLBTHRA | |
| SCHEMBL15211231 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPTALOX15THRBPOLB | |
| SCHEMBL20587925 | 0.75 | SMN1; SMN2 (0.68) | SMN1; SMN2PSMB5PSMB8MAPTALOX15 | |
| SCHEMBL20588968 | 0.74 | SMN1; SMN2 (0.69) | SMN1; SMN2PSMB5MAPTALOX15THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-16 | — | — | US | disclosed |
| EP-3638664-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229193-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223837-A1 | BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | SUCNR1, CBR1, CYP2A13 | SMN1; SMN2 1329/4885PSMB5 232/4885PSMB8 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.